Roche boosts biomanufacturing
15.10.2013 – Swiss Roche AG will invest CHF800m in its global production network for biologic medicines.
The expansion of production capabilities over the next five years will help meet increasing demand for biologic medicines, such as ACTEMRA (tocilizumab), Kadcyla (trastuzumab emtansine) and Perjeta (pertuzumab), alongside providing a strong foundation for the delivery of 39 investigational biologic medicines in the Roche pipeline. Manufacture will be extended across sites in Penzberg (Germany), Basel (Switzerland) as well as Vacaville and Oceanside (USA).
Biologic manufacturing capacity will be increased at sites in Vacaville and Oceanside in California, US, with a planned investment of approximately CHF260m creating around 250 new jobs. In Penzberg, Germany, Roche will invest approximately CHF350m toward increased manufacturing capacity and equipment refurbishment, creating around 200 positions. In addition, construction of an antibody-drug conjugate (ADC) production facility will begin in Basel, Switzerland, through an investment of more than CHF190m, which is expected to create 50 jobs. The investment will support production of Roche’s first approved ADC, Kadcyla, and a further eight ADCs in clinical development.